Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 20/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: Pacira BioSciences, Inc. is under scrutiny due to a class action lawsuit initiated by Kahn Swick & Foti, LLC, with a lead plaintiff application deadline set for March 14, 2025. The lawsuit alleges that the company and its executives failed to disclose critical information during the Class Period, violating federal securities laws. A significant downturn in shareholder value occurred after the invalidation of a key patent for its revenue-driving product, Exparel, which has raised concerns among investors.

Market Sentiment Analysis

CONCERNS & RISKS

  • Pacira is facing a class action lawsuit for not disclosing material information.
  • The company's key patent for its Exparel product was ruled invalid, affecting 80% of revenue.
  • Shares fell over 47% following negative legal news.

Full Press Release Details

NEW ORLEANS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
If you purchased securities of Pacira and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-pcrx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 14, 2025.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything.
On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

The deadline to file lead plaintiff applications is March 14, 2025.

What lawsuit is associated with Pacira BioSciences, Inc.?

The lawsuit is a securities class action for failing to disclose material information.

How much did Pacira's stock price drop after the lawsuit news?

Pacira's stock fell over 47%, dropping from $22.36 to $11.70 per share.

Where is the class action lawsuit pending?

The class action lawsuit is pending in the United States District Court for New Jersey.

Who should be contacted for more information about the lawsuit?

Contact KSF Managing Partner Lewis Kahn at 1-877-515-1850 for more details.

Last updated: Feb 18, 2025